Navigation Links
Echo Therapeutics Announces First Quarter 2012 Financial Results
Date:5/11/2012

in permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
(215) 717-4104

Connect With Us:
- Visit our website at www.echotx.com 
- Follow us on Twitter at www.twitter.com/echotx 
- Join us on Facebook at www.facebook.com/echotx Echo Therapeutics, Inc.Condensed Consolidated Balance Sheets   March 31,2012December 31,2011ASSETSCurrent Assets:Cash and cash equivalents

$
5,910,213$
8,995,571Cash restricted pursuant to vendor letter of credit

250,000250,000Other current assets

317,624317,940Total current assets

6,477,8379,563,511Net property and equipment (including assets under capitalized leases

370,549317,731Intangible assets, net of accumulated amortization

9,625,0009,625,000Restricted cash, deposits and other assets

10,81620,565Total assets

$
,484,202$
9,526,807LIABILITIES AND STOCKHOLDERS' EQUITYCur
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
2. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
3. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
4. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014   Ventana Medical Systems, Inc.  (Ventana), ... has entered into an agreement with Merck KGaA, Darmstadt, ... Serono in the United States ... Merck KGaA,s biopharmaceutical division on the development and commercialization ... using Ventana,s proprietary diagnostic assays. In alignment with Merck ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources Group ... of the U.S. Food and Drug Administration,s (FDA) approval ... binder Velphoro, which was approved by the FDA in ... kidney disease (CKD) patients on dialysis. Other ... Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... A noninvasive optical imaging device developed at ... later occur in the brain and are a ... results from investigators conducting a clinical trial in ... July 15 in an oral presentation at the ... They also were invited by conference organizers to ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Wright & ... trial has been scheduled in July of 2015, in ... Lipitor lawsuits are in the discovery process in ... M. Gergel is presiding over the multidistrict litigation (MDL). ... on behalf of individuals who allege that they took ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 ECS ... who commented, “As a parent of a special needs ... need in the Seattle community for contemporary special education ... an important alternative to students and families in the ... practices and environment for special education. We welcome the ...
(Date:7/13/2014)... 13, 2014 According to The Peripheral ... a comprehensive program that teaches people how to deal ... without medications. This program also provides people with ... peripheral neuropathy , including numbness, prickling, burning, and intense ... that this home treatment program can help people eliminate ...
Breaking Medicine News(10 mins):Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... do minor behavior problems and experiences early in life ... group of researchers has found that the answer may ... experiences lead to behaviors and new experiences that lead ... behavior. , The researchers found that children who had ...
... revenue exceeds $10 billion, COVINGTON, Ky. and ... ASH ) today completed its acquisition of Hercules,Incorporated, ... the world,s most essential needs and industries. Each ... $18.60 in cash and 0.093 of a,share of ...
... ... Business Assets, WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ... ended,September 30, 2008., For the first quarter of fiscal 2009, ... fiscal 2007. This,included product revenue of $8,669,000 for the first quarter ...
... a leading,international manufacturer, marketer, and supplier of protective ... financial,results for the third quarter of 2008., ... were $265.2 million, an,increase of 8.2% over net ... of,2007. Excluding the impact of favorable foreign currency ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, November,19, 2008 at 8:30 a.m. ET. Daniel M. ... be providing a corporate overview., The live presentation ... made,available following the event. The Web cast and recording ...
... N.J., Nov. 13 Pharmos Corporation,(Nasdaq: PARS ) ... Market ("Nasdaq") on November 11, 2008 that the Company ... requires the,Company to have a minimum of $2,500,000 in ... $500,000 of net income,from continuing operations for the most ...
Cached Medicine News:Health News:Cascading effect of even minor early problems may explain serious teen violence 2Health News:Ashland Completes Acquisition of Hercules 2Health News:Ashland Completes Acquisition of Hercules 3Health News:Ashland Completes Acquisition of Hercules 4Health News:Ashland Completes Acquisition of Hercules 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 2Health News:Pregis Announces Third Quarter 2008 Financial Results 3Health News:Pregis Announces Third Quarter 2008 Financial Results 4Health News:Pregis Announces Third Quarter 2008 Financial Results 5Health News:Pregis Announces Third Quarter 2008 Financial Results 6Health News:Pregis Announces Third Quarter 2008 Financial Results 7Health News:Pregis Announces Third Quarter 2008 Financial Results 8Health News:Pregis Announces Third Quarter 2008 Financial Results 9Health News:Pregis Announces Third Quarter 2008 Financial Results 10Health News:Pregis Announces Third Quarter 2008 Financial Results 11Health News:Pregis Announces Third Quarter 2008 Financial Results 12Health News:Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter 2
... Capture vital signs faster, easier, and ... LXi, the latest innovation in multi-parameter ... Spot LXi, you get more parameters ... flexibility to customize it to meet ...
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Medicine Products: